Particularly, the peptides CLP002 and CLP003 exhibited high blocking efficacy against the PD-1/PD-L1 interaction on recombinant PD-L1 protein and PD-L1-expressing tumor cells (Figs. 3 and 4). Here, CD274 is linked to neoplasm.